DigestRedComo funciona
Red
/
Empresas
Im
No verificado

Imbrium Therapeutics L.P.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

7 Comunicados de prensa

Ver todos los comunicados de prensa
09/09/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Sanidad
Industria
Results From Sunobinop Phase 1B Study in Patients With Interstitial Cystitis/Bladder Pain Syndrome Announced
Fuente
Imbrium Therapeutics L.P.
Editor
Business Wire
1.00
0
16/06/2025
Biotecnología
Salud
Oncología
Medicina - Varios
Eventos
Imbrium Therapeutics to Showcase Pipeline Assets Open for Partnership at the BIO International Convention 2025
Fuente
Imbrium Therapeutics L.P.
Editor
Business Wire
1.00
0
11/03/2025
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Potential Treatment for Interstitial Cystitis/Bladder Pain Syndrome
Fuente
Imbrium Therapeutics L.P.
Editor
Business Wire
1.00
0
07/01/2025
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Imbrium Therapeutics Announces Results of a Sunobinop Phase 1b Study in Patients With Overactive Bladder Syndrome
Fuente
Imbrium Therapeutics L.P.
Editor
Business Wire
1.00
0
18/11/2024
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Imbrium Therapeutics Completes First Patient Dosed in Phase 2 Study to Evaluate Sunobinop for the Potential Treatment of Alcohol Use Disorder
Fuente
Imbrium Therapeutics L.P.
Editor
Business Wire
1.00
0
05/08/2024
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Imbrium Therapeutics Submits Investigational New Drug Application to Evaluate Sunobinop for the Potential Treatment of Alcohol Use Disorder
Fuente
Imbrium Therapeutics L.P.
Editor
Business Wire
1.00
0
09/07/2024
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Potential Treatment for Overactive Bladder Syndrome
Fuente
Imbrium Therapeutics L.P.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0